Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain

Grau, Santiago; Salavert, Miguel; Laderas, Juan Carlos Pozo; Vargas, Mercedes; Barrueta, Jon Andoni; Mir, Nuria

doi:10.1016/j.mycmed.2013.05.004

Cited by 12 publications

(19 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Además de las diferencias encontradas en el coste del tratamiento con cada candina en el presente análisis, son necesarias más evidencias que nos permitan concluir que el empleo de una u otra candina supone un impacto considerable en otro tipo de costes (como disminución de estancia hospitalaria o UCI, manejo de efectos adversos, etc.). En este sentido, solo anidulafungina ha demostrado reducir la estancia hospitalaria y de UCI de los pacientes con CI 27 y ser una estrategia coste-efectiva en España 16 .…”

Section: Discussionunclassified

See 1 more Smart Citation

Análisis de costes de tres candinas en el tratamiento de la candidiasis invasora en pacientes adultos no neutropénicos en España

García-Vargas

Mir

Barrueta

2012

Farmacia Hospitalaria

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

“…En el caso de enfermos infectados el aumento era de 12,7 días. El incremento de costes estimado fue de 8.000 D para los colonizados y de 16.000 D para los infectados. Otros costes relacionados con el manejo de la enfemedad están asociados con los fracasos del tratamiento y con el manejo de los acontecimientos adversos 6,7 .…”

Section: Introductionunclassified

Análisis de costes de tres candinas en el tratamiento de la candidiasis invasora en pacientes adultos no neutropénicos en España

García-Vargas

Mir

Barrueta

2012

Farmacia Hospitalaria

Self Cite

View full text Add to dashboard Cite

show abstract

“…Despite a higher cost, echinocandins (anidulafungin, micafungin) have demonstrated to reduce mortality and overall inhospital costs compared to fluconazole, both in the setting of empirical and definite treatment of IC [28][29][30]. Notably, some authors suggest that caspofungin is more cost-effective than fluconazole in the empiric treatment of IC/C when fluconazole resistance is higher than 25% in hospital, reinforcing the importance of knowing the local epidemiology [31].…”

mentioning

confidence: 99%

Treatment of invasive candidiasis: between guidelines and daily clinical practice

Tagliaferri

Menichetti

2015

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

“…Other authors around the globe who have compared the cost-effectiveness of Anidulafungin with Fluconazole for Invasive Fungal Infections, provided findings that are in concordance with our results, suggesting Anidulafungin as a Cost-effective agent over Fluconazole. [27][28][29][30] …”

Section: Discussionmentioning

confidence: 99%

A study on rapid diagnosis (by PCR) and cost-effective treatment of pulmonary mycosis

2018

View full text Add to dashboard Cite

Background: Incidence of Pulmonary Mycosis is rampantly growing in critically ill patients. This study was designed to comparatively evaluate conventional and molecular method-Polymerase Chain Reaction (PCR) for detecting Candida and Aspergillus species in Brocho-Alveolar Lavage (BAL) samples and secondarily to find out the Cost-Effective treatment for Pulmonary Mycosis.Methods: In this study 100 BAL-specimens were collected from patients suspected of Pulmonary Mycosis. These samples were examined for Aspergillus and Candida species by preparation of wet smear using potassium hydroxide, Gram staining, Culture media and Polymerase Chain Reaction (PCR). For Cost-Effectiveness analysis(CEA), a decision tree model was constructed for Anidulafungin and Fluconazole The probability of treatment success and mortality rate were extracted from published Randomized Control Trials. Incremental Cost Effectiveness Ratio (ICER) was calculated.Results: Out of 100 samples, 22 were found to be positive for mycotic infections, 9 were detected as Candida and 13 as Aspergillus. On comparing with KOH and Culture, it was observed that all KOH positive and all Culture positive fungal infections were PCR positive. In no cases PCR negative was identified either culture or KOH positive. This establishes the superiority of PCR over conventional diagnostic methods. Anidulafungin was associated with an Incremental Cost Effectiveness Ratio (ICER) of INR 1,13,217 per LY saved, which was below the implicit ICER threshold for India.Conclusions: PCR is a novel molecular method for early and definitive diagnosis of fungal infection and Aidulafungin appears to be the cost-effective drug for treatment of Pulmonary Mycosis.

show abstract

Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain

Cited by 12 publications

References 50 publications

Análisis de costes de tres candinas en el tratamiento de la candidiasis invasora en pacientes adultos no neutropénicos en España

Análisis de costes de tres candinas en el tratamiento de la candidiasis invasora en pacientes adultos no neutropénicos en España

Treatment of invasive candidiasis: between guidelines and daily clinical practice

A study on rapid diagnosis (by PCR) and cost-effective treatment of pulmonary mycosis

Contact Info

Product

Resources

About